Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer
BMC Cancer - United Kingdom
doi 10.1186/s12885-018-5198-4
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2018
Authors
Publisher
Springer Science and Business Media LLC